oa مراقبة الأدوية العلاجية، الأساسيات والتحسين (مراجعة الخبراء)

References

1. Marshall WJ, Lapsley M, Day A, Ayling R. Clinical biochemistry E-book: Metabolic and clinical aspects.Elsevier Health Sciences; CHAPTER 39 - Therapeutic drug monitoring; 2014pp.767-786.
   [Google Scholar]
2. Dasgupta A. Introduction to therapeutic drug monitoring: Frequently and less frequently monitored drugs.In: Dasgupta A, editor. Therapeutic drug monitoring. Boston: Academic Press; 2012: 1-29.
   [Google Scholar]
3. Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update.Therapeutic Drug Monitoring. 2018;40(5): 526-548.
   [Google Scholar]
4. Zhang Y, Zhang R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs.Drug Testing and Analysis. 2018;10(1): 81-94.
   [Google Scholar]
5. Boyer A, Gruson D, Bouchet S, Clouzeau B, Hoang-Nam B, Vargas F, et al. Aminoglycosides in septic shock.Drug Safety. 2013;36(4): 217-230.
   [Google Scholar]
6. Rybak MJ, Lomaestro BM, Rotscahfer JC, Moellering Jr RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: A summary of consensus recommendations from the nfectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.Clinical Infectious Diseases. 2009;49(3): 325-327.
   [Google Scholar]
7. Mabilat C, Gros MF, Nicolau D, Mouton JW, Textoris J, Roberts JA, et al. Diagnostic and medical needs for therapeutic drug monitoring of antibiotics.European Journal of Clinical Microbiology & Infectious Diseases. 2020;39(5):791–797.
   [Google Scholar]
8. Wicha SG, Märtson AG, Nielsen EI, Koch BC, Friberg LE, Alffenaar JW, et al. From therapeutic drug monitoring to model‐informed precision dosing for antibiotics.Clinical Pharmacology & Therapeutics. 2021;109(4):928–941.
   [Google Scholar]
9. Jacob S, Nair AB. An updated overview on therapeutic drug monitoring of recent antiepileptic drugs.Drugs in R&D. 2016;16(4):303–316.
   [Google Scholar]
10. John J, Loo A, Mazur S, Walsh TJ. Therapeutic drug monitoring of systemic antifungal agents: A pragmatic approach for adult and pediatric patients.Expert Opinion on Drug Metabolism & Toxicology. 2019;15(11):881–895.
    [Google Scholar]
11. Urban AE, Cubała WJ. Therapeutic drug monitoring of atypical antipsychotics.Psychiatria Polska. 2017;51(6):1059–1077.
    [Google Scholar]
12. Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology.Clinical Pharmacology and Therapeutics. 2017;102(5):765–776.
    [Google Scholar]
13. Fobelo Lozano MJ, Serrano Giménez R, Sánchez Fidalgo S. Therapeutic drug monitoring of infliximab in spondyloarthritis.A review of the literature. British Journal of Clinical Pharmacology. 2019;85(10):2264–2279.
    [Google Scholar]
14. Franca R, Curci D, Lucafò M, Decorti G, Stocco G. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease.Expert Opinion on Drug Metabolism & Toxicology. 2019;15(7):527–539.
    [Google Scholar]
15. Hoseyni H, Xu Y, Zhou H. Therapeutic drug monitoring of biologics for inflammatory bowel disease: An answer to optimized treatment? Journal of Clinical Pharmacology.2018;58(7):864–876.
    [Google Scholar]
16. Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.Expert Review of Clinical Immunology. 2019;15(8):837–848.
    [Google Scholar]
17. Restellini S, Khanna R, Afif W. Therapeutic drug monitoring with Ustekinumab and Vedolizumab in inflammatory bowel disease.Inflammatory Bowel Diseases. 2018;24(10):2165–2172.
    [Google Scholar]
18. Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, et al. Therapeutic drug monitoring of biologics during induction to prevent primary non-response.Journal of Crohn's & Colitis. 2020;14(4):542–556.
    [Google Scholar]
19. Mok CC. Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.Expert Review of Clinical Immunology. 2017;13(1):35–41.
    [Google Scholar]
20. Hermans C, Herranz P, Segaert S, Gils A. Current practice of therapeutic drug monitoring of biopharmaceuticals in Psoriasis patients.Therapeutic Drug Monitoring. 2017;39(4):356–359.
    [Google Scholar]
21. Imamura CK. Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties.Drug Metabolism and Pharmacokinetics. 2019;34(1):14–18.
    [Google Scholar]
22. Pasupuleti RR, Tsai P-C, Ponnusamy VK, Pugazhendhi A. Rapid determination of remdesivir (SARS-CoV-2 drug) in human plasma for therapeutic drug monitoring in COVID-19-Patients.Process Biochemistry. 2021;102: PP106-150. .
    [Google Scholar]
23. Tecen-Yucel K, Aras-Atik E, Bayraktar-Ekincioglu A. Does therapeutic drug monitoring of hydroxychloroquine improve treatment outcome in intensive care unit patients with COVID-19.International Journal of Clinical Practice. 2021;75(4):e13894.
    [Google Scholar]
24. Ali AS, Abdelrahman MS, AB RAHMAN AF, Soliman MI. Therapeutic drug monitoring practical guide : Scientific Publishing Center, King Abdulaziz University, 2016 :1-15..
    [Google Scholar]
25. Zhao W, Jacqz-Aigrain E. Principles of therapeutic drug monitoring.Pediatric clinical pharmacology. Springer; 2011: 77–90.
    [Google Scholar]
26. Wong G, Sime FB, Lipman J, Roberts JA. How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients, BMC Infectious Diseases.2014;14(1):288 :1-11.
    [Google Scholar]
27. Burton ME. Applied pharmacokinetics & pharmacodynamics: principles of therapeutic drug monitoring.Lippincott Williams & Wilkins; 2006: 285-327.
    [Google Scholar]
28. Capiau S, Veenhof H, Koster RA, Bergqvist Y, Boettcher M, Halmingh O, et al. Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring.Therapeutic Drug Monitoring. 2019;41(4): 409–430.
    [Google Scholar]
29. Iacuzzi V, Posocco B, Zanchetta M, Gagno S, Poetto AS, Guardascione M, et al. Dried blood spot technique applied in therapeutic drug monitoring of anticancer drugs: A review on conversion methods to correlate plasma and dried blood spot concentrations.Pharmaceutical Research. 2021; 38 :759–778.
    [Google Scholar]
30. Klak A, Pauwels S, Vermeersch P. Preanalytical considerations in therapeutic drug monitoring of immunosuppressants with dried blood spots.Diagnosis (Berlin, Germany). 2019;6(1):57–68.
    [Google Scholar]
31. Martial LC, Aarnoutse RE, Mulder M, Schellekens A, Brüggemann RJM, Burger DM, et al. Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoring.European neuropsychopharmacology. The Journal of the European College of Neuropsychopharmacology. 2017;27(3):205–216.
    [Google Scholar]
32. Min KL, Ryu JY, Chang MJ. Development and clinical applications of the dried blood spot method for therapeutic drug monitoring of anti-epileptic drugs.Basic & Clinical Pharmacology & Toxicology. 2019;125(3):215–236.
    [Google Scholar]
33. Vu DH, Alffenaar JW, Edelbroek PM, Brouwers JR, Uges DR. Dried blood spots: A new tool for tuberculosis treatment optimization.Current Pharmaceutical Design. 2011;17(27):2931–2939.
    [Google Scholar]
34. Kok MG, Fillet M. Volumetric absorptive microsampling: Current advances and applications.Journal of Pharmaceutical and Biomedical Analysis. (2018);147:288-296.
    [Google Scholar]
35. Kang J-S, Lee M-H. Overview of therapeutic drug monitoring.The Korean Journal of Internal Medicine. 2009;24(1):1-10.
    [Google Scholar]
36. Dasgupta A, Datta P. Analytical techniques for measuring concentrations of therapeutic drugs in biological fluids.Handbook of drug monitoring methods. Springer; 2008:67–86.
    [Google Scholar]
37. Cui JJ, Wang LY, Tan ZR, Zhou HH, Zhan X, Yin JY. Mass spectrometry-based personalized drug therapy.Mass Spectrometry Reviews. 2020;39(5–6):523–552.
    [Google Scholar]
38. Seger C, Salzmann L. After another decade: LC-MS/MS became routine in clinical diagnostics.Clinical Biochemistry. 2020;82:2–11.
    [Google Scholar]
39. Tuzimski T, Petruczynik A. Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM).Molecules (Basel, Switzerland). 2020;25(17):2-69.
    [Google Scholar]
40. van Nuland M, Rosing H, Schellens JHM, Beijnen JH. Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology.Biomedical Chromatography : BMC. 2020;34(1):e4623.
    [Google Scholar]
41. Vogeser M, Seger C. A decade of HPLC-MS/MS in the routine clinical laboratory – goals for further developments.Clinical Biochemistry. 2008;41(9):649–662.
    [Google Scholar]
42. Zhang Y, Zhang R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs.Drug Testing and Analysis. 2018;10(1):81–94.
    [Google Scholar]
43. Zheng YZ, Wang S. Advances in antifungal drug measurement by liquid chromatography-mass spectrometry.Clinica Chimica Acta; International Journal of Clinical Chemistry. 2019;491:132–145.
    [Google Scholar]
44. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.Epilepsia. 2008;49(7):1239–1276.
    [Google Scholar]
45. Zhang Y, Zhang R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs.Drug Test Anal. 2018;10(1):81-94.
    [Google Scholar]
46. Nwobodo N. Therapeutic drug monitoring in a developing nation: A clinical guide.JRSM Open. 2014;5(8):1-5.
    [Google Scholar]
47. Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring: A systematic review.Therapeutic Drug Monitoring. 2005;27(1):10–17.
    [Google Scholar]
48. Vithanachchi DT, Maujean A, Downes MJ, Scuffham P. A comprehensive review of economic evaluations of therapeutic drug monitoring interventions for cancer treatments.British Journal of Clinical Pharmacology. 2021;87(2):271–283.
    [Google Scholar]
49. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM. Therapeutic drug monitoring.Drugs. 2003;63(8):741–753.
    [Google Scholar]
50. Winter ME, Katcher BS, Koda-Kimble MA. Basic clinical pharmacokinetics.Philadelphia: Lippincott Williams & Wilkins; 2009. 73-97.
    [Google Scholar]
51. Ghiculescu R. Therapeutic drug monitoring: Which drugs, why, when and how to do it.Aust Prescr 2008;31:42-4.
    [Google Scholar]
52. Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs.Pharmacopsychiatry. 2006;39(4):121–127.
    [Google Scholar]
53. Karami F, Ranjbar S, Ghasemi Y, Negahdaripour M. Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples.Journal of Pharmaceutical Analysis. 2019;9(6):373–391.
    [Google Scholar]
54. Feghali M, Venkataramanan R, Caritis S, editors. Pharmacokinetics of drugs in pregnancy.Semin Perinatol. 2015, 39(7): 512–519..
    [Google Scholar]
55. Mayor S. Pharmacokinetics: Optimising safe and effective prescribing.Prescriber. 2017;28(3):45–48.
    [Google Scholar]
56. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: An overview.Cold Spring Harbor Perspectives in Medicine. 2016;(6): 1-18 (a027029).
    [Google Scholar]
57. Grześk G, Stolarek W, Kasprzak M, Krzyżanowski M, Szadujkis-Szadurska K, Wiciński M, et al. Therapeutic drug monitoring of digoxin–20 years of experience.Pharmacological Reports. 2018;70(1):184–189.
    [Google Scholar]
58. Gajjar BM, Shah AM, Patel PM. The pattern of adverse drug events to antiepileptic drugs: A cross-sectional study at a tertiary care teaching hospital.National Journal of Physiology, Pharmacy and Pharmacology. 2016;6(6):616–621.
    [Google Scholar]
59. van den Anker, J. , Reed, M.D., Allegaert, K. and Kearns, G.L. (2018), Developmental Changes in Pharmacokinetics and Pharmacodynamics. The Journal of Clinical Pharmacology, 58: S10-S25.
    [Google Scholar]
60. Wu MF, Lim WH. Phenytoin: A guide to therapeutic drug monitoring.Proceedings of Singapore Healthcare. 2013;22(3):198–202.
    [Google Scholar]
61. Panday D, Panday K, Basnet M, Kafle S, Shah B, Rauniar G. Therapeutic drug monitoring of carbamazepine.International Journal of Neurorehabilitation. 2017;4(245):1-5 (doi:10.4172/2376-0281.1000245).
    [Google Scholar]
62. Byun JI, Chu K, Sunwoo JS, Moon J, Kim TJ, Lim JA, et al. Mega‐dose phenobarbital therapy for super‐refractory status epilepticus.Epileptic Disorders. 2015;17(4):444–452.
    [Google Scholar]
63. Hauptman, PJ. , Blume, SW., Lewis, EF., Ward, S. Digoxin toxicity and use of digoxin immune fab: insights from a national hospital database. JACC: Heart Failure. 2016; 4(5):357-364.
    [Google Scholar]
64. Fisher, ES. , Curry, SC.). Evaluation and treatment of acetaminophen toxicity. Advances in Pharmacology. 2019; 85: 263-272.‏ .
    [Google Scholar]
65. Almohammde S, Alhodian H, Almofareh S, Alshehri S, Almasri DM, Ghoneim RH. A survey of therapeutic drug monitoring in a teaching hospital.Saudi Journal of Biological Sciences. 2021;28(1):744–747.
    [Google Scholar]
66. Clarke W. Overview of therapeutic drug monitoring.Clinical challenges in therapeutic drug monitoring. Elsevier. 2016:1–15.
    [Google Scholar]
67. Khairi LNHM, Ahmad FS, Anuar ASM, Omar NAW, Muhammad NN, Jamal NA, et al. Improving the appropriateness of therapeutic drug monitoring sampling in Hospital Sultanah Nur Zahirah, Kuala Terengganu.Q Bulletin. 2020;1(29):28–35.
    [Google Scholar]
68. Hussain M, Sahudin S, Yussof I. Exploring the use of computer-aided learning modules (CAL) to enhance the teaching and learning of pharmacokinetics to pharmacy students.Journal of Young Pharmacists. 2020;12(4):354-359.
    [Google Scholar]
69. Allison K. Adherence through education: A call to clinicians to educate all patients on medication use.Mental Health Clinician. 2012;2(4):83–85.
    [Google Scholar]
70. Mathes T, Großpietsch K, Neugebauer EA, Pieper D. Interventions to increase adherence in patients taking immunosuppressive drugs after kidney transplantation: A systematic review of controlled trials.Systematic Reviews. 2017;6(1):1–14.
    [Google Scholar]
71. Ali AS, Farouq MF, Al-Faify KA. Pharmacokinetic approach for optimizing gentamicin use in neonates during the first week of life.Indian Journal of Pharmacology. 2012;44(1): 36–40.
    [Google Scholar]
72. Ali AS, Al-Nasser MS, Sattar MAA, Alkreathy HM, Al-Amma MN, Alsulaimani RA, et al. Major adverse effects associated with tacrolimus (Fk506) based regimen among Saudi Kidney transplant patients.Journal of Pharmaceutical Research International. 2018:1–8.
    [Google Scholar]
73. Islam SI. Pharmacogenomics and therapeutic drug monitoring: The challenge in drug safety.International Journal of Integrative Biology. 2008;4:62–66.
    [Google Scholar]
74. Al-Nasser M, Ali A, Sattar M, Abdulfattah E, Khan L. Therapeutic drug monitoring of tacrolimus in Saudi Kidney transplant patients.Journal of Nephrology & Therapeutics. 2016;6(264):DOI: 10.4172/2161-0959.1000264.
    [Google Scholar]
75. Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools.Clinical Pharmacokinetics. 2013;52(1):9-22.
    [Google Scholar]
76. Drennan P, Doogue M, van Hal SJ, Chin P. Bayesian therapeutic drug monitoring software: Past, present and future.International Journal of Pharmacokinetics. 2018;3:109–114.
    [Google Scholar]
77. Albers LJ, Ozdemir V. Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics.Current Medicinal Chemistry. 2004;11(3):297–312.
    [Google Scholar]
78. de Leon J. Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics.Neuropharmacology. 2020;168: (107656), 1-12. .
    [Google Scholar]
79. Doki K. [Use of pharmacogenetic information for therapeutic drug monitoring of an antiarrhythmic drug].Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan. 2018;138(9):1145–1150.
    [Google Scholar]
80. Jaquenoud Sirot E, van der Velden JW, Rentsch K, Eap CB, Baumann P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.Drug Safety. 2006;29(9):735–768.
    [Google Scholar]
81. Owusu Obeng A, Egelund EF, Alsultan A, Peloquin CA, Johnson JA. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: Are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy.2014;34(7):703–718.
    [Google Scholar]
82. Plesničar BK, Plesničar A. Therapeutic drug monitoring and pharmacogenetics – is this a way towards creative psychopharmacotherapy? Psychiatria Danubina.2014;26(2):96–99.
    [Google Scholar]
83. Stieffenhofer V, Hiemke C. Pharmacogenetics, therapeutic drug monitoring and non compliance .Therapeutische Umschau Revue therapeutique. 2010;67(6):309–315.
    [Google Scholar]